|
|
|
|
Pharma manufacturing strategy now extends beyond cost and capacity, with resilience, flexibility, alignment, and market proximity supporting lasting success.
|
|
|
|
|
Second-source planning builds flexibility, strengthens transfer readiness, and supports long-term supply continuity amid changing capacity needs and market opportunities.
|
|
|
|
|
Minimize development and scale-up risk for complex OSD products through integrated formulation, process development, and manufacturing capabilities that enhance readiness.
|
|
|
|
|
Commercial success comes from treating tech transfer as a strategic collaboration. Flexible processes, early supply chain planning, and partnerships protect timelines and drive long‑term performance.
|
|
|
|
|
|
|
New U.S. tariffs are reshaping pharma manufacturing. Early action to assess exposure and pursue onshoring can cut risk, protect margins, and strengthen supply chains.
|
|
|
|
|
|
|
Bora Pharmaceuticals is a global CDMO specializing in small molecule drug product development and manufacturing from clinical through commercial supply.
|
|
|
